Our Business Segments

Our Business Segments

Granules currently supplies to customers in over 80+ countries.

Over the years, Granules has evolved itself from being an API manufacturer to a company that has a strong presence across the value chain. This enabled us to transform into a complete global pharmaceutical player with presence in APIs, PFIs and FD. Cost efficiencies and continuous innovation continue to remain a core focus for the company that we strive to achieve through innovation at the development stage, ongoing continuous improvements and through various strategies across supply chain and manufacturing.

  • Global leader in the manufacturing of Paracetamol, Metformin, Guaifenesin, and Methocarbamol
  • Cost-effective and efficient manufacturer of APIs with a focus on continuous manufacturing
  • State of the art manufacturing facilities with DCS (Distributed Control systems) to ensure minimal human intervention while maximizing productivity and quality
  • Contract manufacturer for strategic customers across the globe
  • Marketed to over 80 countries across the world
  • Pioneered the concept of commercializing PFIs or Pre formulation Intermediates, with objective to reduce cost economics of products
  • Largest PFI producer in India with a batch processing capability of six tonnes
  • "Drum to Hopper"- Reduced capital expenditure, development & Testing costs for customer
  • Contract manufacturer for strategic customers across the globe
  • Integrated manufacturer for Rx and OTC products; Immediate Release, Extended Release, Delayed Release, Multi particulate Pellet system-based products
  • Ability to develop and manufacture Tablets, Capsules, Press fits, Oral Solutions, Suspensions and Powder for Oral Solutions
  • Ability to package in bulk, bottles, and blisters
  • Global dossier filings with a focus on North America, Europe and South Africa amongst others
  • Contract manufacturer for strategic customers across the globe

Core Business

  • Focus on volume-based product.
  • First line of treatment.
  • Efficiency driven manufacturing.
  • Business to Business (B2B) model.

Paracetamol, Ibuprofen, Metformin,
Methocarbamol and Guaifenesin

US Generics

  • Focus on R&D with our integrated structure that includes manufacturing and marketing capabilities with ‘Make in America’ concept.
  • Business-to-Consumer model (B2C).

Focus on developing controlled substances and niche/differentiated modified and extendedrelease products in varied dosage forms

Emerging Business

  • Fully integrated facility to offer APIs and FDs in various therapeutic areas.
  • Multi-product and multi-stage API to FD manufacturing site.
  • Adding MUPs capabilities for modified & delayed release technology.

Losartan, Cetirizine and Fexofenadine